SCHEMBL8438595

SCHEMBL8438595

OC1CNCCC1N1CCC(c2ccccc2)CC1

nearest known ligand 0.97

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 11/20 0.79
CYP2D6 P10635 2/20 0.66
TSHR P16473 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
CYP1A2 P05177 1/20 0.66
CYP2C9 P11712 1/20 0.66
SIGMAR1 Q99720 1/20 0.66
ALDH1A1 P00352 1/20 0.64
APEX1 P27695 1/20 0.64
BLM P54132 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9980730 0.88 SLC18A3 (1.00) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
SCHEMBL29418998 0.88 SLC18A3 (1.00) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
SCHEMBL7828818 0.81 SLC18A3 (0.72) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
Vesamicol SCHEMBL4499985 0.80 SLC18A3 (1.00) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
Vesamicol SCHEMBL4499984 0.80 SLC18A3 (1.00) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
Vesamicol SCHEMBL571598 0.80 SLC18A3 (1.00) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
Vesamicol SCHEMBL12648665 0.80 SLC18A3 (1.00) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
Trifluoroacetic Acid SCHEMBL6071640 0.79 SLC18A3 (0.64) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
SCHEMBL4072060 0.78 SLC18A3 (0.64) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2
Vesamicol SCHEMBL8984052 0.77 SLC18A3 (0.94) SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658131-B2 Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand WASHINGTON UNIVERSITY (US) 2014-02-25 US disclosed
US-20110311447-A1 Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand WASHINGTON UNIVERSITY (US) 2011-12-22 US disclosed
US-5876694-A NON-INVASIVELY MAPPING CHOLINERGIC INNERVATION IN A LIVING BRAIN COMPRISES INJECTING THE BRAIN WITH A RADIOLABELLED VESAMICOL DERIVATIVE, MAGNETIC RESONANCE IMAGING REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1999-03-02 US disclosed
US-5789420-A Azavesamicols REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1998-08-04 US disclosed
US-5338852-A Azavesamicols REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1994-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311447-A1 Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand SIGMAR1, TMEM97, OPRM1 SLC18A3 248/4885CYP2D6 548/4885TSHR 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.